{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:58:50Z","timestamp":1761512330407},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1016\/j.berh.2005.06.009","type":"journal-article","created":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T21:56:07Z","timestamp":1165010167000},"page":"965-973","source":"Crossref","is-referenced-by-count":5,"title":["Who will benefit from antiresorptive treatment (bisphosphonates)?"],"prefix":"10.1016","volume":"19","author":[{"given":"Socrates E.","family":"Papapoulos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2005.06.009_bib1","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.berh.2005.06.009_bib2","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2005.06.009_bib3","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"The Journal of the American Medical Association"},{"key":"10.1016\/j.berh.2005.06.009_bib4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporosis International"},{"key":"10.1016\/j.berh.2005.06.009_bib5","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jc.85.11.4118","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.berh.2005.06.009_bib6","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"The Journal of the American Medical Association"},{"key":"10.1016\/j.berh.2005.06.009_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) study group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporosis International"},{"key":"10.1016\/j.berh.2005.06.009_bib8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.berh.2005.06.009_bib9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.berh.2005.06.009_bib10","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1359\/jbmr.2002.17.6.1057","article-title":"Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized, placebo-controlled clinical trial with a 2-year open extension","volume":"17","author":"Brumsen","year":"2002","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.berh.2005.06.009_bib11","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1359\/jbmr.040116","article-title":"Clodronate reduces vertebral fracture risk in women with postmenopausal osteoporosis: results of a double-blind, placebo-controlled 3-year study","volume":"19","author":"McCloskey","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.berh.2005.06.009_bib12","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","author":"Chesnut","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.berh.2005.06.009_bib13","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","article-title":"Meta-analysis of alendronate for the treatment of postmenopausal women","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.berh.2005.06.009_bib14","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1210\/er.2001-3002","article-title":"Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.berh.2005.06.009_bib15","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00198-004-1725-z","article-title":"Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women","volume":"16","author":"Papapoulos","year":"2005","journal-title":"Osteoporosis International"},{"key":"10.1016\/j.berh.2005.06.009_bib16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","article-title":"Pharmacokinetics\/pharmacodynamics of bisphosphonates","volume":"44","author":"Cremers","year":"2005","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.berh.2005.06.009_bib17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s002239900713","article-title":"Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis","volume":"65","author":"Gonelli","year":"1999","journal-title":"Calcified Tissue International"},{"key":"10.1016\/j.berh.2005.06.009_bib18","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1359\/JBMR.0301231","article-title":"Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate","volume":"19","author":"Seibel","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.berh.2005.06.009_bib19","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine and vertebral fracture in alendronate-treated women: the fracture intervention trial","volume":"19","author":"Bauer","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.berh.2005.06.009_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF02408534","article-title":"Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate in rats","volume":"32","author":"Reitsma","year":"1980","journal-title":"Calcified Tissue International"},{"issue":"supplement 1","key":"10.1016\/j.berh.2005.06.009_bib21","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S8756-3282(09)80009-4","article-title":"The use of bisphosphonates in the treatment of osteoporosis","volume":"13","author":"Papapoulos","year":"1992","journal-title":"Bone"},{"key":"10.1016\/j.berh.2005.06.009_bib22","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.berh.2005.06.009_bib23","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstrom","year":"2004","journal-title":"Calcified Tissue International"},{"issue":"supplement 2","key":"10.1016\/j.berh.2005.06.009_bib24","first-page":"S45","article-title":"Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women","volume":"19","author":"Recker","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.berh.2005.06.009_bib25","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00223-004-0039-7","article-title":"5 years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis","volume":"75","author":"Ste-Marie","year":"2004","journal-title":"Calcified Tissue International"},{"issue":"supplement 2","key":"10.1016\/j.berh.2005.06.009_bib26","first-page":"S45","article-title":"A 5 year randomized trial of the long-term efficacy and safety of alendronate: the FIT long-term extension (FLEX)","volume":"19","author":"Black","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"key":"10.1016\/j.berh.2005.06.009_bib27","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1210\/jc.2003-031672","article-title":"Prevention of postmenopausal bone loss: six-year results from the Early Postmenopausal Intervention Cohort Study","volume":"89","author":"McClung","year":"2004","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.berh.2005.06.009_bib28","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone mineral density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause"},{"key":"10.1016\/j.berh.2005.06.009_bib29","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1210\/jc.80.12.3465","article-title":"Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate","volume":"80","author":"Landman","year":"1995","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"supplement 1","key":"10.1016\/j.berh.2005.06.009_bib30","first-page":"S448","article-title":"Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women?","volume":"19","author":"Cramer","year":"2004","journal-title":"Journal of Bone and Mineral Research"},{"issue":"supplement 1","key":"10.1016\/j.berh.2005.06.009_bib31","first-page":"s99","article-title":"Treatment discontinuation effects on bone turnover and BMD with risedronate","volume":"34","author":"Watts","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.berh.2005.06.009_bib32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: a randomized, double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"Journal of Bone and Mineral Research"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694205000811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694205000811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T23:54:51Z","timestamp":1547164491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694205000811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["S1521694205000811"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2005.06.009","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}